{"id":"NCT00866918","sponsor":"Children's Oncology Group","briefTitle":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia","officialTitle":"Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (TrisenoxÂ® ) During Consolidation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-03-09","primaryCompletion":"2015-06-30","completion":"2022-09-30","firstPosted":"2009-03-23","resultsPosted":"2017-04-04","lastUpdate":"2022-10-25"},"enrollment":106,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Childhood Acute Promyelocytic Leukemia With PML-RARA","Myeloid Neoplasm"],"interventions":[{"type":"DRUG","name":"Arsenic Trioxide","otherNames":["Arsenic (III) Oxide","Arsenic Sesquioxide","Arsenous Acid","Arsenous Acid Anhydride","Arsenous Oxide","ATO","Trisenox","White Arsenic"]},{"type":"DRUG","name":"Cytarabine","otherNames":[".beta.-Cytosine arabinoside","1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone","1-.beta.-D-Arabinofuranosylcytosine","1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone","1-Beta-D-arabinofuranosylcytosine","1.beta.-D-Arabinofuranosylcytosine","2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-","2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-","Alexan","Ara-C","ARA-cell","Arabine","Arabinofuranosylcytosine","Arabinosylcytosine","Aracytidine","Aracytin","Aracytine","Beta-Cytosine Arabinoside","CHX-3311","Cytarabinum","Cytarbel","Cytosar","Cytosine Arabinoside","Cytosine-.beta.-arabinoside","Cytosine-beta-arabinoside","Erpalfa","Starasid","Tarabine PFS","U 19920","U-19920","Udicil","WR-28453"]},{"type":"OTHER","name":"Diagnostic Laboratory Biomarker Analysis","otherNames":[]},{"type":"DRUG","name":"Idarubicin","otherNames":["4-Demethoxydaunomycin","4-Demethoxydaunorubicin","4-DMDR"]},{"type":"DRUG","name":"Mercaptopurine","otherNames":["3H-Purine-6-thiol","6 MP","6 Thiohypoxanthine","6 Thiopurine","6-Mercaptopurine","6-Mercaptopurine Monohydrate","6-MP","6-Purinethiol","6-Thiopurine","6-Thioxopurine","6H-Purine-6-thione, 1,7-dihydro- (9CI)","7-Mercapto-1,3,4,6-tetrazaindene","Alti-Mercaptopurine","Azathiopurine","Bw 57-323H","Flocofil","Ismipur","Leukerin","Leupurin","Mercaleukim","Mercaleukin","Mercaptina","Mercaptopurinum","Mercapurin","Mern","NCI-C04886","Puri-Nethol","Purimethol","Purine, 6-mercapto-","Purine-6-thiol (8CI)","Purine-6-thiol, monohydrate","Purinethiol","Purinethol","U-4748","WR-2785"]},{"type":"DRUG","name":"Methotrexate","otherNames":["Abitrexate","Alpha-Methopterin","Amethopterin","Brimexate","CL 14377","CL-14377","Emtexate","Emthexat","Emthexate","Farmitrexat","Fauldexato","Folex","Folex PFS","Lantarel","Ledertrexate","Lumexon","Maxtrex","Medsatrexate","Metex","Methoblastin","Methotrexate LPF","Methotrexate Methylaminopterin","Methotrexatum","Metotrexato","Metrotex","Mexate","Mexate-AQ","MTX","Novatrex","Rheumatrex","Texate","Tremetex","Trexeron","Trixilem","WR-19039"]},{"type":"DRUG","name":"Mitoxantrone Hydrochloride","otherNames":["CL 232315","DHAD","DHAQ","Dihydroxyanthracenedione Dihydrochloride","Mitoxantrone Dihydrochloride","Mitoxantroni Hydrochloridum","Mitozantrone Hydrochloride","Mitroxone","Neotalem","Novantrone","Onkotrone","Pralifan"]},{"type":"DRUG","name":"Tretinoin","otherNames":["2,4,6,8-Nonatetraenoic acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-","Aberel","Airol","Aknoten","all trans-Retinoic acid","All-trans Retinoic Acid","All-trans Vitamin A Acid","all-trans-Retinoic acid","all-trans-Vitamin A acid","ATRA","Avita","beta-Retinoic Acid","Cordes Vas","Dermairol","Epi-Aberel","Eudyna","Renova","Retin-A","Retin-A MICRO","Retin-A-Micro","Retinoic Acid","Retisol-A","Ro 5488","Stieva-A","Stieva-A Forte","Trans Retinoic Acid","Trans Vitamin A Acid","trans-Retinoic Acid","Tretinoinum","Vesanoid","Vitamin A Acid","Vitamin A acid, all-trans-","Vitinoin"]}],"arms":[{"label":"Arm I (standard risk, combination chemotherapy)","type":"EXPERIMENTAL"},{"label":"Arm II (high risk, combination chemotherapy)","type":"EXPERIMENTAL"}],"summary":"This phase III trial is studying combination chemotherapy to see how well it works in treating young patients with newly diagnosed acute promyelocytic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.","primaryOutcome":{"measure":"Event-free Survival (EFS)","timeFrame":"At 3 years from study entry","effectByArm":[{"arm":"Standard Risk","deltaMin":95.4,"sd":null},{"arm":"High Risk","deltaMin":82.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":121,"countries":["United States","Canada","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":["https://nctn-data-archive.nci.nih.gov/"]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":66},"commonTop":["Febrile neutropenia","Infections and infestations - Other, specify","Electrocardiogram QT corrected interval prolonged","Hypokalemia","Alanine aminotransferase increased"]}}